NCT07072325View on ClinicalTrials.gov

Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 31, 2028

Conditions

Malignant NeoplasmHead &Amp; Neck CancerHead and Neck CancerAdvanced Head and Neck Carcinoma

Interventions

DRUG

CD-001

CD-001 administered as an intravenous (lV)infusion.

All Listed Sponsors

lead

West China Hospital

OTHER